Diseases of the Digestive System - Small Intestines, Large Intestines & Rectum, Phase III

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

Volunteers
Health Professionals

What is the purpose of this trial?

Brief Summary:

This is a Phase 3, randomized, double-blind, placebo-controlled study to demonstrate the effect of oral ozanimod as maintenance therapy in subjects with moderately to severely active Crohn's Disease.

Trial with
Celgene Corporation
Ages
18 years - 75 years
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Elizabeth Ruggiero

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Deborah Proctor, MD
Professor of Medicine (Digestive Diseases); Medical Director, Inflammatory Bowel Disease Program; Site Director, Universidad del Valle, Cali, Columbia and Yale/Stanford, Johnson and Johnson Global Health Scholar Program; President and Board of Directors, Honduras Children's Project, Internal Medicine

Sub-Investigators

Last Updated
07/23/2024
Study HIC
#2000024497